Sonnet Biotherapeutics Holdings Inc Asset Resilience Ratio
Sonnet Biotherapeutics Holdings Inc asset resilience ratio. Sonnet Biotherapeutics Holdings Inc (SONN) has an Asset Resilience Ratio of 0.02% as of March 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Sonnet Biotherapeutics Holdings Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sonnet Biotherapeutics Holdings Inc (None–None)
Asset resilience ratio of Sonnet Biotherapeutics Holdings Inc from None to None. This chart shows how Sonnet Biotherapeutics Holdings Inc's Asset Resilience Ratio has changed over time. Read debt load of Sonnet Biotherapeutics Holdings Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Sonnet Biotherapeutics Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SONN current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.84K | 0.02% |
| Total Liquid Assets | $10.84K | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Sonnet Biotherapeutics Holdings Inc maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sonnet Biotherapeutics Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Sonnet Biotherapeutics Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Sonnet Biotherapeutics Holdings Inc Asset Resilience Ratio by Year (None–None)
Sonnet Biotherapeutics Holdings Inc asset resilience ratio by year from None to None. The table below shows the annual Asset Resilience Ratio data for Sonnet Biotherapeutics Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About Sonnet Biotherapeutics Holdings Inc
As of December 2, 2025, Sonnet BioTherapeutics Holdings, Inc. was acquired by Hyperliquid Strategies Inc, in a reverse merger transaction. Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that bin… Read more